Sanofi: Stronger Launches And A New R&D Reset Keep The Re-Rating Case Alive

Summary Q2 strengthened earnings visibility, with higher guidance and continued Dupixent momentum supporting the 2026 outlook. Newer launches are scaling faster, giving Sanofi a clearer path toward a more diversified revenue base. The new R&D leadership adds credibility to pipeline prioritization and could improve capital allocation across internal and external innovation. Valuation remains discounted versus peers despite stronger growth visibility, supporting our Buy rating. Panama7/iStock Editorial via Getty Images In our last update, we provided a deep dive into Sanofi ( SNY ) ( SNYNF ) patent cliff and exposure to its major drug (Dupixent). We maintained our Buy rating despite the market’s continued concern This article was written by Mare Evidence Lab 6.17K Followers Follow Buy-side hedge professionals conducting fundamental, income oriented, long term analysis across sectors globally in developed markets. Please shoot us a message or leave a comment to discuss ideas.DISCLOSURE: All of our articles are a matter of opinion, informed as they might be, and must be treated as such. We take no responsibility for your investments but wish you best of luck. Analyst’s Disclosure: I/we have a beneficial long position in the shares of SNY, SNYNF either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.